Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Spot Assay Validated for Enzyme Deficiency Disease

By LabMedica International staff writers
Posted on 15 Sep 2011
A fluorometric method of α-L-iduronidase (IDUA) enzyme activity determination using dried blood spots (DBS) on filter paper has been tested. More...


A reference interval value to IDUA activity using a DBS assay has been evaluated as to whether this assay could be an efficient tool to diagnose patients with mucopolysaccharidosis type I (MPS I) disease.

Scientists at the Federal University of São Paulo (Brazil) collected blood samples from 164 Brazilian healthy volunteers (HV) from both genders, 69 men and 95 women, age range from 18 to 73 years, who did not show any clinical evidence of chronic disease and/or other genetic disease. The validation group (VG) comprised DBS and leukocyte samples from 36 individuals clinically suspected of MPS I, sent by physicians from 12 different Brazilian States. Cutoff values initially used to discriminate HV from MPS I patients were 1.1 µmol/L/hour and 0.02 nmol/mg protein/hour for DBS and leukocyte assays, respectively.

The IDUA activity range on HV DBS samples were 1.40 µmol/L/hour to 7.78 µmol/L/hour. In the VG test group, 11 of the 36 individuals clinically suspected of MPS I had the diagnosis confirmed by DBS and a reference leukocyte assay. A new proposed cutoff value of 1.5 µmol/L/hour had the sensitivity, specificity, and predictive values of 100%. The authors suggest that the interpretation of IDUA activity results should be performed according to the following criteria: for activity results lower than 1.2 µmol/L/hour, the DBS method is an accurate tool to diagnose MPS I, together with the evaluation of clinical symptoms and other laboratory results; for activity results between 1.2 µmol/L/hour and 1.8 µmol/L/hour, another diagnostic assay should be performed in leukocyte, plasma, or fibroblast samples to confirm these suggestive results; and for activity results higher than 1.8 µmol/L/hour, the DBS assay is reliable and safe to exclude the diagnosis of MPS I.

Mucopolysaccharidosis type I, also known as Hurler Syndrome, is caused by a deficiency of the enzyme α-L-iduronidase that leads to the accumulation of glycosaminoglycans, such as heparan sulfate, in lysosomes. MPS I patients present a spectrum ranging from a severe to an attenuated phenotype. The authors concluded that the determination of IDUA activity using a DBS assay is an accurate tool for MPS I diagnosis. However, it is extremely important to assure that all recommendations for collection, transport, and storage are correctly followed to guarantee the quality of the sample. The article was published online on July 22, 2011, in the Journal of Clinical Laboratory Analysis.

Related Links:
Federal University of São Paulo







Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.